PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Pharmacokinetic/pharmacodynamic profiles of remazolam besylate were compared in patients with
impaired and normal renal function in the ICU, and safety was assessed by recording
hemodynamic parameters and adverse events.